Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 5Completed 5Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 97Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 10Recurrence 8Leukemia 8Neoplasm, Residual 6Hematologic Neoplasms 6Myeloproliferative Disorders 5Lymphoma, T-Cell, Peripheral 5Leukemia, Biphenotypic, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Monocytic, Acute 3Anemia, Refractory, with Excess of Blasts 3Myeloid Malignancy 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2GATA2 Deficiency 2Breast Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Pathologic Complete Response 1

Interventions

Specimen Handling 7ruxolitinib 6Stem Cell Transplantation 5Cyclophosphamide 4Biopsy 4fludarabine 3Mycophenolic Acid 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3Whole-Body Irradiation 2Tacrolimus 2Sirolimus 2Methotrexate 2Melphalan 2Hematopoietic Stem Cell Transplantation 2Blood Component Removal 2thymoglobulin 1talazoparib 1tagraxofusp 1reparixin 1poly ICLC 1piperine 1pegylated granulocyte colony-stimulating factor 1merphos 1letermovir 1iadademstat 1fludarabine phosphate 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Primary Myelofibrosis × Azacitidine × Clear all
NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

University of Chicago

Phase 1 Recruiting
18 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡